Citi downgraded Genmab to Sell from Neutral with a DKK 1,765 price target. While Citi has the “upmost respect” for Genmab’s antibody generating platforms and management team, its revised assumptions point to an unattractive risk/reward profile. The analyst now assumes Genmab is unsuccessful in ongoing Darzalex arbitration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
- Biotech Alert: Searches spiking for these stocks today
- Genmab price target lowered to DKK 2,800 from DKK 3,000 at Barclays
- TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
- Pfizer and Genmab’s sBLA for Tivdak accepted by the FDA
- Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
